A case report of hemophagocytic lymphohistiocytosis secondary to tislelizumab and bevacizumab combination therapy for renal cell carcinoma

Key Points

• Hemophagocytic lymphohistiocytosis occurred due to tislelizumab and bevacizumab combination therapy.
• This case marks the first documented instance of HLH linked to this treatment for renal cell carcinoma.
• Assessment involved detailed clinical observation of a patient with renal cell carcinoma receiving the drug combination.
• These findings may indicate potential safety issues and warrant further investigation into treatment protocols.

Abstract